propranolol has been researched along with roflumilast in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alen, J; Boland, S; Boumans, N; Bourin, A; Castermans, K; Defert, O; Leysen, D; Panitti, L; Vanormelingen, J | 1 |
| Albrecht, W; Bauer, SM; Laufer, SA; Unger, A | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
3 other study(ies) available for propranolol and roflumilast
| Article | Year |
|---|---|
Novel Roflumilast analogs as soft PDE4 inhibitors.
Topics: Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Humans; Hydrolysis; Molecular Structure; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2014 |
Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Discovery; Humans; Imidazoles; Inflammation; Mitogen-Activated Protein Kinase 14; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha | 2017 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |